Thyroid Cancer Risk Stratification (ATA)
Stratifies differentiated thyroid cancer recurrence risk using ATA 2015 guidelines. Guides extent of surgery, radioiodine (RAI), and surveillance intensity.
Score interpretation
→ Thyroid lobectomy may suffice for T1-T2 low-risk; no RAI for low-risk; TSH 0.5-2 mU/L suppression target; annual Tg + USS for 5 years
→ Total thyroidectomy; RAI 30-100 mCi if nodal disease or extrathyroidal extension; TSH 0.1-0.5 mU/L; 6-monthly Tg + USS; endocrine surgery MDT
→ Total thyroidectomy + therapeutic neck dissection; high-dose RAI (100-200 mCi); TSH <0.1 mU/L suppression; whole body RAI scan; 3-monthly surveillance; clinical trial for poorly differentiated/anaplastic
Interpretation bands for the Thyroid Cancer ATA Risk. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Levothyroxine · Thyroid Hormone
- Liothyronine Sodium (T3) · Thyroid Hormone (T3)
- Potassium Iodide / Lugol's Solution · Thyroid Blocking Agent / Pre-operative Thyroid Preparation
- Liothyronine sodium (T3) · Thyroid hormone (T3)
- Levothyroxine sodium · Thyroid hormone (T4)
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.